Biktarvy is a single tablet containing bictegravir, emtricitabine and tenofovir alafenamide, and it is the most widely prescribed HIV treatment regimen in the United States. It is also one of the most expensive routinely dispensed drugs in American retail pharmacy, which makes the gap between its sticker price and what patients actually pay unusually wide.

This guide separates the two. The first half is the real price of the product: what Gilead lists, what pharmacies pay to buy it, and what a cash register would ring up. The second half is the machinery that exists to make sure a person living with HIV does not pay that. All figures were verified on September 2, 2026.

What Does Biktarvy Cost Without Insurance?

Three independent price sources anchor this table, and they land close together, which is what you expect from a brand drug with no generic competition. Gilead publishes the wholesale acquisition cost on its own pricing site. CMS publishes the National Average Drug Acquisition Cost, a survey of what retail pharmacies actually pay their wholesalers. SingleCare publishes live retail and discount-card prices by chain.

Price benchmarkLowTypicalHigh
Biktarvy 30 tablets (50-200-25 mg)$3,994.36$4,216.00$5,342.06
Per tablet$133.15$140.53$178.07
Pharmacy acquisition cost (NADAC), 30 tablets$4,101.99$4,101.99$4,101.99
Annualized at 12 fills$47,932$50,592$64,105
Gilead’s stated typical patient cost$0/mo$0-$5/mo$5/mo

Gilead’s own price page states that the list price of Biktarvy is $4,216 per month, notes that list price is also known as wholesale acquisition cost, and dates that figure to January 1, 2026 for a 30-day supply. The same page says that “typically a person taking BIKTARVY pays between $0 and $5 per month,” a claim it attributes to IQVIA prescription data covering January through December 2025.

CMS NADAC data effective August 19, 2026 puts the acquisition cost at $136.73311 per tablet for the adult 50-200-25 mg strength, which is $4,101.99 for a 30-count bottle. The pediatric 30-120-15 mg tablet is $136.64291, essentially the same.

SingleCare’s Biktarvy page, updated September 2, 2026, shows an average retail cash price of $5,342.06 against a card price of $3,994.36. Its per-chain data on 30 tablets of the 50-200-25 mg strength runs from $3,997.36 at Kroger and Harris Teeter to $4,112.06 at CVS, $4,148.06 at Walgreens, $4,242.09 at Publix and $4,340.27 at Food Lion, with card prices only about $3 below each retail figure.

That last detail is the tell. On a genericized drug, a discount card routinely cuts the price by 60% or 80%. Here it saves three dollars, because the pharmacy is already selling within a few percent of what it paid.

Why the discount card barely moves the number

Look at the arithmetic. A pharmacy buys Biktarvy for roughly $4,102 a bottle. If it sells to a cash customer for $4,148, it has made $46 on a $4,000 purchase. There is no margin left for a coupon to claw back, and no cheaper chemically equivalent product to switch you to.

Compare that to the genericized end of the same drug class. CMS NADAC data effective August 19, 2026 prices generic emtricitabine and tenofovir disoproxil fumarate at $0.50510 per tablet, about $15 for a month. Brand Truvada is $59.62 a tablet and Descovy is $74.94. The entire spread between $15 and $4,102 is patent status, not chemistry.

What Drives the Price

No generic exists, and none is coming soon. The FDA Orange Book lists Biktarvy under NDA 210251, approved February 7, 2018 for the adult strength and October 7, 2021 for the pediatric strength, with Gilead Sciences as the sole application holder. In an October 6, 2025 Form 8-K, Gilead disclosed that it had settled patent litigation with Lupin, Cipla and Laurus Labs, all three of which had filed abbreviated new drug applications, and stated that under those agreements “no generic entry is expected prior to April 1, 2036 in the United States.” That single sentence is the most important cost fact on this page. It means the cash price is set by one company for another decade.

It is a fixed-dose combination of three drugs. Bictegravir, the integrase inhibitor, is the patented component. Emtricitabine and tenofovir alafenamide are also Gilead molecules. Combining them into one daily tablet is the product’s clinical selling point and also the reason no piece of it can be swapped for something cheaper.

Which pharmacy fills it. The spread is real but small in percentage terms. SingleCare’s September 2026 data shows a $343 gap between the cheapest and most expensive chain on the same 30 tablets, which is about 8%. On a $4,000 prescription, 8% is $343 a month or roughly $4,100 a year, so it is still worth shopping.

Whether the prescription runs through a benefit at all. Biktarvy is filled at a pharmacy under a pharmacy benefit, not administered in a clinic. That means a cash payer sees the whole price at once rather than receiving a bill later, and it means the assistance programs below have to be arranged before you walk up to the counter, not after.

The 340B ceiling price applies to clinics, not to you. Federally qualified health centers, Ryan White clinics and other covered entities buy outpatient drugs at the 340B ceiling price. Under the HHS final rule published in the Federal Register on January 5, 2017, that ceiling is the average manufacturer price minus the Medicaid unit rebate amount, and for a new single-source or innovator drug the estimate is wholesale acquisition cost minus a rebate percentage of 23.1%. Applied to a $4,216 list price, a 23.1% floor discount is about $973 a month, and actual ceiling prices on established brand drugs are typically deeper. The individual 340B prices are not published, but the practical consequence is simple: a 340B clinic can afford to give you Biktarvy in a way a retail pharmacy cannot.

Cash Price vs. Insurance

For Biktarvy, running the drug through coverage almost always wins, and the reason is arithmetic rather than principle. A $4,216 monthly drug will exhaust an individual deductible in one or two fills and will push most people to their out-of-pocket maximum within a few months, after which the plan pays everything. A cash payment does none of that.

If you have commercial insurance, the Gilead Advancing Access Co-pay Savings Program covers up to $7,200 per calendar year for Biktarvy with no monthly cap. Read the accumulator language before relying on it: Gilead states it may cut the assistance to $25 per claim if it determines your insurer runs an accumulator adjustment program that keeps coupon dollars from counting toward your deductible.

If you are uninsured, the copay card is explicitly off the table. Gilead’s posted terms say the savings program “is not insurance and is not intended to substitute for insurance” and that “uninsured and cash-paying patients are not eligible.” Uninsured patients go to the Patient Assistance Program instead, which supplies the drug free rather than reducing a copay. That is a better deal, not a worse one, and it is the single most important thing to know if you are pricing this drug with no coverage.

How to Pay Less

  1. Apply to Gilead Advancing Access before you fill anything. The Patient Assistance Program provides Biktarvy at no charge to eligible uninsured US residents. Enrollment lasts up to 12 months with ongoing eligibility checks, and you can re-enroll, though Gilead notes that becoming eligible for Medicaid or ADAP may end your PAP eligibility because those programs take over. You can enroll online or by fax through gileadadvancingaccess.com.

  2. Get into your state ADAP. Every state and territory runs an AIDS Drug Assistance Program under Ryan White Part B. Terms vary by state, and the income cutoffs are far more generous than most people assume. Florida’s Department of Health, for example, states it covers the costs of HIV medications directly for individuals at or below 400% of the federal poverty level, and that Biktarvy and Descovy are on its direct-dispense formulary. Ask a case manager at any HIV clinic to walk the application with you.

  3. Fill at a Ryan White or federally qualified health center pharmacy. These are 340B covered entities, buying at a statutory ceiling price rather than retail. They are also where the case managers who run ADAP and PAP paperwork actually sit. Our guide to free and sliding-scale clinics explains how to find one and what to expect on income documentation.

  4. If you must pay cash for a month, price the chains first. SingleCare’s September 2026 data shows a $343 spread on the same 30 tablets between the cheapest and most expensive chain. Our comparison of GoodRx vs. SingleCare covers how to check both cards in a couple of minutes, and our fair price checker gives you a sanity check on any quote.

  5. Never let a lapse become a bill you negotiate later. If a fill has already gone through at full price and you are staring at a four-figure pharmacy charge, treat it like any other medical bill rather than a fixed price. Our guide to negotiating medical bills covers the scripts, and if the charge came from a hospital-owned pharmacy or clinic, hospital charity care may wipe it out entirely.

  6. Ask specifically whether monitoring labs are bundled. Biktarvy is not the only line item in HIV care. Viral load, CD4 counts and metabolic panels recur, and they are billed separately. Our blood work cost guide prices the routine panels, and STD testing costs covers the screening that usually accompanies them.

Bottom Line

Biktarvy’s real cash price is about $4,000 to $5,350 a month, or $48,000 to $64,000 a year, and it is not going to fall on its own before April 2036. What makes this drug different from almost everything else on this site is that the sticker price is close to irrelevant. Gilead’s own data says a typical patient pays $0 to $5 a month, and the programs that produce that number are open to uninsured people specifically.

If you are uninsured and prescribed Biktarvy, the correct first move is not to shop pharmacies. It is to call Gilead Advancing Access at the number on its enrollment page and to ask an HIV clinic case manager to start an ADAP application the same week. Shopping the cash price is what you do while those applications are pending, not instead of them.

For the prevention side of the same shelf, see our PrEP cost guide and our guides to Apretude and Cabenuva, the long-acting injectables. If you are pricing hepatitis C alongside HIV care, our hepatitis C treatment cost guide and Epclusa cost guide cover that shelf, and our doctor visit cost guide prices the appointments in between.